HiSoft (HSFT) (NOV) (FN) (GILD) (HRC) (ISRG) Price Targets Changed

HiSoft Technology International Limited (NASDAQ: HSFT), National-Oilwell Varco, Inc. (NYSE: NOV), Fabrinet (NYSE: FN), Gilead Sciences, Inc. (NASDAQ: GILD), Hill-Rom Holdings, Inc. (NYSE: HRC) and Intuitive Surgical, Inc. (NASDAQ: ISRG) price targets adjusted by analysts.

National-Oilwell Varco, Inc. (NOV) had its price target lowered by Morgan Keegan from $100.00 to $84.00. They have an “Outperform” rating on the company.

Fabrinet Ordinary (FN) had its price target lowered by Stifel Nicolaus from $30.00 to $25.00. They have a “Buy” rating on the company.

Gilead Sciences, Inc. (GILD) had its price target raised by Summer Street Research from $42.00 to $54.00. They have a “Buy” rating on the company.

Hill-Rom Holdings, Inc. (HRC) had its price target lowered by Morgan Keegan from $45.00 to $40.00. They have an “Outperform” rating on the company.

HiSoft Technology International Limited (HSFT) had its price target raised by Stifel Nicolaus from $20.00 to $22.00. They have a “Buy” rating on the company.

Intuitive Surgical, Inc. (ISRG) had its price target lowered by Morgan Keegan from $385.00 to $340.00. They have a “Market Perform” rating on the company.

Teradata (TDC) (CY) (ENTR) (ISRG) (SLAB) (SMSC) Get New Coverage

Teradata Co. (NYSE: TDC), Cypress Semi (NYSE: CY), Entropic Communications (NASDAQ: ENTR), Intuitive Surgical, Inc. (NASDAQ: ISRG), Silicon Laboratories (NASDAQ: SLAB) and Standard Microsystems Co. (NASDAQ: SMSC) getting new coverage from analysts.

Goldman Sachs (NYSE:GS) initiated coverage on Teradata Co. (TDC). They placed a “Neutral” rating on the company.

Wunderlich initiated coverage on Cypress Semi (CY). They placed a “Buy” rating and a price target of $25.00 on the company.

Wunderlich initiated coverage on Entropic Communications (ENTR). They placed a “Buy” rating and a price target of $8.00 on the company.

ThinkEquity initiated coverage on Intuitive Surgical, Inc. (ISRG). They placed a “Hold” rating on the company.

Wunderlich initiated coverage on Silicon Laboratories (SLAB). They placed a “Hold” rating and a price target of $33.00 on the company.

Wunderlich initiated coverage on Standard Microsystems Co. (SMSC). They placed a “Buy” rating and a price target of $36.00 on the company.

Ratings on (ISRG) (MCC) (PLT) (PM) (SBUX) Reiterated

Ratings on Intuitive Surgical, Inc. (NASDAQ: ISRG), Medley Capital (NYSE: MCC), Plantronics (NYSE: PLT), Philip Morris (NYSE: PM) and Starbucks (NASDAQ: SBUX) reiterated by analysts.

Morgan Keegan reiterated a “market perform” rating on Intuitive Surgical, Inc. (ISRG).

Gilford Securities reiterated a “buy” rating on Medley Capital (MCC).

Wedbush reiterated a “neutral” rating on Plantronics (PLT).

Morgan Stanley (NYSE:MS) reiterated an “overweight” rating on Philip Morris (PM).

Morgan Stanley reiterated an “overweight” rating on Starbucks (SBUX).

Big Movers (ISRG) (ESL) (NFX) (FMX) (AG) on May 6

Among the big, positive movers on Friday, May 6, were Intuitive Surgical (ISRG), Esterline Technologies (ESL), Newfield Exploration (NFX), Fomento Economico (FMX) and First Majestic Silver (AG).

Intuitive Surgical (ISRG) jumped $1.44, to close at $348.38, a gain of 0.42 percent.

Esterline Technologies (ESL) was up $1.43 on the day to close at $72.61, a gain of 2.01 percent.

Newfield Exploration (NFX) climbed $1.42 to close at $67.60, a gain of 2.15 percent.

Fomento Economico (FMX) rose $1.41 to close the session at $61.89, a gain of 2.33 percent.

First Majestic Silver (AG) was up $1.41 to end the day at $18.24, a gain of 8.38 percent.

St. Jude Medical (STJ) Earnings Drop Ends Streak

Shares of St. Jude Medical (NYSE:STJ) are trading strong even after a disappointing quarter where net income for St. Jude Medical, Inc. was down to $233.4 million, or 71 cents a share, vs. $238.6 million, or 73 cents a share last year in the same quarter, a decline of 2.2 percent.

Revenue jumped for the quarter, rising 9 percent to $1.38 billion.

St. Jude Medical missed on the average analyst estimate of 78 cents a share. Estimates ranged from 77 cents a share to 80 cents a share.

St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “During the first quarter, we continued to make good progress in developing the new growth drivers we need to return to double-digit sales growth on a sustainable basis. Our gross margin has strengthened, we have continued to invest in research and development at an elevated rate, and our sales and earnings growth outlook have both improved. We are off to a good start making 2011 another very successful year for St. Jude Medical.”

Major competitors of St. Jude Medical include Medtronic, Inc. (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Intuitive Surgical, Inc. (NASDAQ:ISRG), Johnson & Johnson (NYSE:JNJ), and Edwards Lifesciences Corp. (NYSE:EW).

St. Jude Medical was trading at $52.75, gaining $1.75, or 3.43 percent, as of 1:22 PM EDT.

Goldman (NYSE:GS) Keeps "Sell" Rating on Intuitive Surgical (NASDAQ:ISRG)

Even though Goldman Sachs (NSYE:GS) raised their price target and EPS estimates on Intuitive Surgical (NASDAQ:ISRG), they remain negative on the company, keeping their "Sell" rating on it.

Goldman raised full year 2011-2014 EPS estimates from $9.92/$11.66/$13.42/$15.08 to $10.79/$12.68/$14.75/$16.63.

The reasoning for Goldman is the strong results for Intuitive Surgical in the fourth quarter were driven by inventory stocking, an it appears their penetration in the U.S. market is reaching peak levels, as evidenced in the 9 percent drop in initial system placements.

Intuitive closed Monday at $327.99, gaining $1.41, or 0.43 percent. Goldman raised their price target on them from $220 to $270.

Intuitive Surgical (NASDAQ:ISRG) Shares Explode on Strong Guidance

Shares of Intuitive Surgical (NASDAQ:ISRG) are soaring today, as the company beat expectations and gave strong guidance for 2011.

Canaccord says, "Q4 results beat expectations on the top and bottom lines. 2011 guidance for 16-20% revenue growth is solid and could prove to be conservative. We think ISRG still has room to run in penetrating the hysterectomy market and it also has opportunities to sustain strong procedure growth for the next couple of years through mainstream adoption of emerging robotic-assisted procedures (thoracic, lung, trans-oral, etc.)...We are incrementally more positive on the name but would refrain from buying into strength. The stock is indicating to open at $315-320 and we think it is fairly valued at those levels but would be buyers on a pull back."

Canaccord reiterates a "Hold" rating on Intuitive Surgical (ISRG), which was trading at $332.44, gaining $42.61, or 14.70 percent, as of 2:34 PM EST. Canaccord has a price target of $330 on Intuitive Surgical.

Intuitive Surgical (NASDAQ:ISRG) Trading as Steep Premium to Peers

Looking ahead, Brigantine sees Intuitive Surgical (NASDAQ:ISRG) needed a strong macro-economic environment to grow, along with expanded penetration of da Vinci.

Brigantine says, "We maintain a Hold rating and think the prospect of upside to our conservative projections will hinge on an improved macro environment, along with the company’s ability to drive system upgrades and increase da Vinci’s penetration in surgical categories outside of hysterectomy and prostatectomy. We see Q4 revenues rising 6.6% to $344.4M and see EPS of $2.05 vs. the year-ago $1.95. In our view, valuation expansion will be challenging with ISRG priced at 29x our 2011 EPS estimate and 7.5x estimated 2011 revenues, sharply ahead of peers.

"...However, with the stock trading at steep premiums to peers we remain on the sidelines and calculate fair value in the $275-$300 range."

Brigantine Advisors reiterates a "Hold" rating on Intuitive Surgical (ISRG), which closed Tuesday at $296.32, gaining $8.04, or 2.79 percent.